Direct oral anticoagulants in antiphospholipid syndrome

被引：2
|
作者：
de Carvalho, Jozelio Freire [1 ]
Oliveira de Andrade, Daniele Castro [2 ]
Levy, Roger A. [3 ]
机构：
[1] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil
[2] Univ Sao Paulo, Fac Med, Div Reumatol, Sao Paulo, SP, Brazil
[3] Univ Estado Rio de Janeiro, Div Reumatol, Rio De Janeiro, RJ, Brazil
来源：
REVISTA BRASILEIRA DE REUMATOLOGIA | 2016年 / 56卷 / 06期
关键词：
THROMBOEMBOLISM; RIVAROXABAN;
D O I：
10.1016/j.rbre.2016.09.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：469 / 470
页数：2
相关论文
共 50 条
  • [31] Comparative Analysis of Direct Oral Anticoagulants and Vitamin K Antagonists in Antiphospholipid Syndrome Patients
    Elsebaie, Maha A. T.
    Wickham, Zoe Alexandra
    Debragga, Stephanie
    Li, Juan
    Gaddh, Manila
    BLOOD, 2021, 138
  • [32] Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension
    Porres-Aguilar, Mateo
    Kahn, Susan R.
    Hirsch, Andrew M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (03) : 755 - 756
  • [33] Rethinking the use of direct oral anticoagulants for secondary thromboprophylaxis in patients with thrombotic antiphospholipid syndrome
    Franco-Moreno, Anabel
    Izquierdo-Martinez, Aida
    Ancos-Aracil, Cristina
    DRUG DISCOVERIES AND THERAPEUTICS, 2024, 18 (04): : 213 - 219
  • [34] Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)
    Moreira Balbi, Gustavo Guimaraes
    Pacheco, Marcelo de Souza
    Monticielo, Odirlei Andre
    Funke, Andreas
    Danowski, Adriana
    Santiago, Mittermayer Barreto
    Staub, Henrique Luiz
    Rego, Jozelia
    Oliveira de Andrade, Danieli Castro
    ADVANCES IN RHEUMATOLOGY, 2020, 60 (01)
  • [35] Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)
    Gustavo Guimarães Moreira Balbi
    Marcelo de Souza Pacheco
    Odirlei Andre Monticielo
    Andreas Funke
    Adriana Danowski
    Mittermayer Barreto Santiago
    Henrique Luiz Staub
    Jozelia Rêgo
    Danieli Castro Oliveira de Andrade
    Advances in Rheumatology, 60
  • [36] Direct Oral Anticoagulants in Antiphospholipid Syndrome-Associated Venous Thromboembolism: Real World Evidence
    Hwang, Hun-Gyu
    Lee, Ju Hyun
    Kim, Sang-A
    Kim, Yang-Ki
    Kim, Myung-Shin
    Hong, Junshik
    Yhim, Ho-Young
    Bang, Soo-Mee
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (36)
  • [37] Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis.
    Cerda, Pau
    Becattini, Cecilia
    Iriarte, Adriana
    Hernandez, Josefina Cortes
    Corbella, Xavier
    Riera-Mestre, Antoni
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 79 : 43 - 50
  • [38] Successful secondary thromboprophylaxis with direct oral anticoagulants for a patient with catastrophic antiphospholipid syndrome A case report
    Nhan Hieu Dinh
    Beaupha, Suzanne Monivong Cheanh
    MEDICINE, 2020, 99 (26) : E20811
  • [39] Effectiveness and Safety of the Direct Oral Anticoagulants in Low-Risk Antiphospholipid Syndrome: A Case Series
    Kwan, Vickie
    Kaplovitch, Eric
    Selby, Rita
    Abdulrehman, Jameel
    BLOOD, 2020, 136
  • [40] Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines
    Pastori, Daniele
    Menichelli, Danilo
    Cammisotto, Vittoria
    Pignatelli, Pasquale
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
12345